Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte(PCVX) Seeking Alpha·2024-09-08 13:00MicroStockHub Vaxcyte, Inc. (NASDAQ:PCVX) is developing next-generation vaccines to prevent and treat bacterial infections through its novel Cell-Free Protein Synthesis [XpressCF] platform. PCVX's technology overcomes the limitations of conventional, cell-based vaccine approaches, delivering broad-spectrum vaccines. Its main value drivers are VAX-31 and VAX-24, which are pneumococcal conjugate vaccines that protect against invasive pneumococcal disease [IPD]. VAX-31 is in Phase 1/2 trials and is quickly pro ...